BIOMAT Database Logo BIOMAT Database Logo

Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes. 2003

P Quatresooz, and G E Piérard
Department of Dermatopathology, University Hospital Sart Tilman, Liège, Belgium.

Dermal dendrocytes (DDs) are dendritic cells that exhibit immunoreactivity for factor XIIIa, and are frequently found in conjunction with basal cell carcinomas (BCCs). Imiquimod was applied to 12 superficial BCCs every 3 days for 8 weeks. One week after completion of treatment, seven lesions appeared to have resolved, while five displayed evidence of residual BCC. Prior to initiation of treatment, the seven imiquimod-responsive BCCs were surrounded by numerous DDs, whereas the five imiquimod-resistant BCCs had fewer DDs next to them at the time of entry into the study. It appears that the pretreatment density in DDs may affect the efficacy of imiquimod in eradicating skin tumours.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002280 Carcinoma, Basal Cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471) Carcinoma, Basal Cell, Pigmented,Epithelioma, Basal Cell,Rodent Ulcer,Ulcer, Rodent,Basal Cell Carcinoma,Basal Cell Carcinomas,Basal Cell Epithelioma,Basal Cell Epitheliomas,Carcinomas, Basal Cell,Epitheliomas, Basal Cell,Rodent Ulcers,Ulcers, Rodent
D003713 Dendritic Cells Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). Dendritic Cells, Interdigitating,Interdigitating Cells,Plasmacytoid Dendritic Cells,Veiled Cells,Dendritic Cells, Interstitial,Dendritic Cells, Plasmacytoid,Interdigitating Dendritic Cells,Interstitial Dendritic Cells,Cell, Dendritic,Cell, Interdigitating,Cell, Interdigitating Dendritic,Cell, Interstitial Dendritic,Cell, Plasmacytoid Dendritic,Cell, Veiled,Cells, Dendritic,Cells, Interdigitating,Cells, Interdigitating Dendritic,Cells, Interstitial Dendritic,Cells, Plasmacytoid Dendritic,Cells, Veiled,Dendritic Cell,Dendritic Cell, Interdigitating,Dendritic Cell, Interstitial,Dendritic Cell, Plasmacytoid,Interdigitating Cell,Interdigitating Dendritic Cell,Interstitial Dendritic Cell,Plasmacytoid Dendritic Cell,Veiled Cell
D005153 Facial Neoplasms New abnormal growth of tissue in the FACE. Facial Neoplasm,Neoplasm, Facial,Neoplasms, Facial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077271 Imiquimod A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS. 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine,Aldara,R 837,R-837,S 26308,S-26308,Zyclara,R837
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

P Quatresooz, and G E Piérard
Factor XIIIa-positive dendrocytes in malignant melanoma.
May 1999, Journal of cutaneous pathology,
P Quatresooz, and G E Piérard
Dermal dendrocytes and other factor XIIIa-positive cells.
December 1993, The Journal of pathology,
P Quatresooz, and G E Piérard
Imiquimod for Superficial Basal Cell Carcinomas.
January 2020, International ophthalmology clinics,
P Quatresooz, and G E Piérard
Factor-XIIIa-positive dendrocytes and the dermal microvascular unit.
January 1990, Dermatologica,
P Quatresooz, and G E Piérard
[Dermal dendrocytes and factor XIIIa in normal and pathological skin].
January 1993, Annales de dermatologie et de venereologie,
P Quatresooz, and G E Piérard
Solitary fibrous tumor is rich in factor XIIIa+ dendrocytes.
October 2002, The American Journal of dermatopathology,
P Quatresooz, and G E Piérard
Factor XIIIa-positive dendrocytes and proliferative activity of cutaneous cancers.
September 1996, Virchows Archiv : an international journal of pathology,
P Quatresooz, and G E Piérard
Imiquimod to treat basal cell and squamous cell carcinomas.
July 2005, American family physician,
P Quatresooz, and G E Piérard
Increased submucosal factor XIIIa-positive dendrocytes in oral lichen planus.
March 1994, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology,
P Quatresooz, and G E Piérard
Relationship of factor XIIIa-positive dermal dendrocytes to Kaposi's sarcoma.
August 1991, Archives of pathology & laboratory medicine,
Copied contents to your clipboard!